Kelsey Moody

Kelsey Moody is an Affiliated Faculty member in the Department of Physics at Syracuse University and serves as CEO and Founder of ICHOR Therapeutics. Her research focuses on translational research and the biology of aging, with a particular emphasis on molecular mechanisms underlying longevity and age-related diseases.

Education includes a PhD in Biochemistry and Molecular Biology from the University of Miami (2019), an MBA in Risk Management from Concordia University Wisconsin (2013), and a BS in Cellular Biochemistry and Psychology from SUNY Plattsburgh (2010).

Her research interests span translational medicine, aging biology, and drug development. Key areas include nanoparticle toxicity studies, DNA repair mechanisms in long-lived species, and enzymatic solutions for age-related ocular diseases like macular degeneration. Her work bridges basic science with clinical applications, aiming to extend healthspan through molecular interventions.

Notable publications (2017–2020) explore topics such as C60 toxicity, SIRT6-mediated DNA repair, and A2E burden reduction in retinal diseases. Awards include recognition as a 2018 '40 under Forty' by the CNY Business Journal and a 2019 Groundbreaker Achievement Award nomination in MedTech.

Moody’s professional activities include leading ICHOR Therapeutics, a company likely focused on translating her research into therapeutic solutions. Her work exemplifies the intersection of academic research and biotech entrepreneurship.